Key points:
- Avacta shares up 8%
- AVA3996 selected for preclinical development
- The pre|CISIONTM chemistry is used to alter chemotherapy drugs
- Avacta Group PLC Stock Forecast
Shares of Avacta have risen just over 8% Tuesday after the company announced the next pre|CISIONTM drug candidate, AVA3996, has been selected for preclinical development.
The company’s pre|CISIONTM chemistry is used to alter chemotherapy drugs to make them inactive in the circulation until they enter the tumour micro-environment where they are then activated by an enzyme.
As a result, Avacta says the platform offers a way to reduce exposure to and improve the safety of cancer drugs by increasing the tolerability of chemotherapies.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Avacta explained that it reviewed efficacy studies and selected AVA3996 as a candidate for preclinical development. The aim for the company is a Clinical Trial Authorisation (CTA) and Investigational New Drug (IND) filing in the first half of 2023.
The first-in-human Phase 1 clinical trial is forecast to begin in the second half of 2023.
Dr Alastair Smith, CEO of Avacta Group, commented: “We are excited by the early pre-clinical data for AVA3996, the second of Avacta’s pre|CISIONTM pro-drugs following on from AVA6000. The pre|CISIONTM platform has the potential to generate a significant pipeline of safer, better tolerated chemotherapies to treat a wide range of cancers. It represents a major commercial opportunity and the principal value driver for the Group.”
Avacta shares are currently trading around the 79p area.
